TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma

By afschroeder • May 17, 2026

Galsky MD, Drakaki A, Basu A, McGregor B, Bedke J, Loriot Y, Kikuchi E, Guo J, Garmezy B, Sridhar SS, Singh P, Koshkin VS, Fleming M, Klauss G, Lin D, Liu C, Apolo AB, Powles T. TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma. Future Oncol. 2026 May 16:1-10. doi: 10.1080/14796694.2026.2663956. Epub ahead of print. PMID: 42142358.

Tags: Antibody–drug conjugate (ADC), Bladder cancer, datopotamab deruxtecan (Dato-DXd), Hematology/Oncology, locally advanced, metastatic, platinum-based chemotherapy, Publications, Trophoblast cell surface antigen 2 (TROP2), urothelial carcinoma

Related Posts

Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer

Swisher EM, Konecny G, Cohen J, Colon-Otero G, Danziger N, Lin DI, Li G, Quintanilha JCF, Decker B, Ross JS, Gearing M, Baker K, Scott[...]

Whole-protein screening and multi-modal profiling of antigen-specific CD4+ T cells at single-cell resolution

Zhang R, Qi J, McKasson M, Choi J, Gutierrez V, Brennan C, Hong S, Chour W, Ng RH, Xie J, Yuan D, Webster A, Sidhu[...]

Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy

Shachar E, Rotkop G, Haas R, Frankenthal R, Kamara D, Demirjian M, Kwan L, Cummings S, Roscow B, Salani R, Spellman PT, Karlan B, Chase[...]